Journal News

MCP: How radiotherapies
vanquish cancer cells

John Arnst
Aug. 1, 2017

Tumor-shredding therapies aren't created equal. When someone with cancer decides to treat the cellular aberration with radiation therapy, as more than 50 percent of cancer patients now do, their primary options are X-rays or particle beams. Despite being available at only a handful of treatment centers worldwide, particle beams, which use protons or carbon ions, possess a number of benefits over traditional X-rays.

 

The effects of the beams on the mechanisms that govern signaling within cells remain largely unexplored. A recent paper in the journal Molecular & Cellular Proteomics sheds some light on this matter.

To better understand the regulatory effects that the particle-based techniques have on the structure and signaling pathways of cancerous cells, researchers at the German Cancer Research Center, Heidelberg University and Heidelberg Ion Beam Therapy Center applied a combination of high-resolution mass spectrometry and SILAC to irradiated human lung adenocarcinoma cells. SILAC is short for stable isotope labeling by amino acids in cell culture; by incorporating amino acids labeled with heavy isotopes into cell cultures and comparing those cells’ mass spectrometry peaks to those of identical, untreated cell cultures, researchers can examine the effects of an outside agent, such as radiation, on the protein makeup of a culture.

“The research interest is just finding out what radiation is doing to cells, to humans and to tissues,” says senior author Martina Schnölzer at the center’s Functional Proteome Analysis unit. “As a chemist, it was really interesting to work together with the radiation oncologists, because my background is more proteomics and not medicine.”

Whereas X-rays destroy cancer cells by inflicting strand breaks on DNA’s double-helix structure, which can be fixed by DNA repair mechanisms, protons and carbon ions tear the genetic structure apart with complex double-strand breaks, which cannot be repaired. This gives proton and carbon ion beams a larger relative biological effectiveness than X-rays, meaning they kill more cancer cells than X-rays do at the same dose. Additionally, particle beams deposit their energy in a more focused manner than X-rays, damaging to a lesser extent the healthy tissues surrounding tumors.

The researchers separated cultures of the human lung cancer cell line into two groups that were fed amino acids with heavy isotopes or light isotopes and irradiated subgroups of the heavy-labeled cells with x-rays, carbon ions or protons. They then performed a phosphopeptide enrichment to increase the concentration of phosphorylated proteins in each sample before subjecting the cells to mass spectrometry to identify changes that had occurred at the protein structure level and which sites had phosphate molecules added or removed. The addition or removal of these molecules is a key indicator that cells are attempting to mitigate damage and is known in aggregate as the phosphoproteome.

While the researchers observed only limited effects on lung cells at the protein level, they noticed altered phosphorylation regulation on 181 different protein sites, or residues, 151 of which had not been previously been known to be affected by irradiation.

“We’ve looked at differential quantification of the proteins and found that there is little happening as an initial event as a consequence of radiation, whereas the phosphoproteome is massively (dysregulated),” says senior co-author Amir Abdollahi at the center’s Division for Molecular and Translational Radiation Oncology. This information will be helpful for designing future studies that examine the effects of radiotherapy, ionizing radiation and space radiation on cellular signaling processes, he says.

Future work for Schnölzer and Abdollahi will involve looking at the effects of radiation on a longer timescale to understand late effects of irradiation and examining its effects on pathways other than phosphorylation signaling.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
John Arnst

John Arnst was a science writer for ASBMB Today.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Living in a bubble
Annual Meeting

Living in a bubble

Sept. 29, 2022

This symposium, Protein Machines and Disorder, will be part of #DiscoverBMB 2023.

Keep your friends close and your RNAs closer
Annual Meeting

Keep your friends close and your RNAs closer

Sept. 29, 2022

This symposium, Regulation of RNA, will be part of #DiscoverBMB 2023.

A membrane ATPase without transporter activity
Journal News

A membrane ATPase without transporter activity

Sept. 28, 2022

A classic article in the Journal of Biological Chemistry reflects on Guido Guidotti’s laboratory and the search for CD39.

The era of “smart” organelles
Annual Meeting

The era of “smart” organelles

Sept. 28, 2022

This symposium, Organelles, Mechanisms and Phase Properties of Cellular Quality Control, will be part of #DiscoverBMB 2023.

Lipids, lipids everywhere!
Annual Meeting

Lipids, lipids everywhere!

Sept. 27, 2022

This symposium, Lipid Dynamics and Signals in Membrane and Protein Structure, will be part of #DiscoverBMB 2023.

A target to prevent kidney injury by chemotherapy
Journal News

A target to prevent kidney injury by chemotherapy

Sept. 27, 2022

“Many people don’t realize that the side effects of chemotherapy are not limited to hair loss, diarrhea and nausea.”